VALID Study Shows Efficacy of Blood-Based Test for Lung Transplant Patients
The VALID study was designed to investigate the effectiveness in determining the risk that a lung allograft is being rejected.
Read MorePosted by Chris Wolski | Jun 1, 2022 | Molecular Diagnostics |
The VALID study was designed to investigate the effectiveness in determining the risk that a lung allograft is being rejected.
Read MorePosted by Chris Wolski | May 26, 2022 | Cancer |
Liquid biopsy is proving itself as both an efficacious and cost-effective way to provide a cancer diagnosis to patients.
Read MorePosted by Andy Lundin | May 20, 2022 | Cancer |
Researchers identified cancer biomarkers based on a type of genetic modification that predicts the type of tumor immune environment and patient outcomes.
Read MorePosted by Andy Lundin | May 18, 2022 | Cancer, Company News |
Delfi Diagnostics has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center’s Biomarker Development Program.
Read MorePosted by Andy Lundin | May 10, 2022 | Cancer, Company News |
Datar announced a contract with Artemis DNA, which provides Next Generation Sequencing genetic testing and diagnostic laboratory services.
Read More